ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial

Autor: Pedro Giavina-Bianchi, MD, PhD, Eric Cua, MD, Karine Risso, MD, Véronique Mondain, MD, Anaïs Vissian, MSc, Cécile Joie, MSc, Philippe Pouletty, MD, Paul Gineste, PharmD, Hartmut J. Ehrlich, MD, PhD, Jorge Kalil, MD, PhD

Publikováno v: Journal of Allergy and Clinical Immunology: Global, Vol 2, Iss 4, Pp 100140- (2023)

Background: ABX464 (obefazimod) is a small molecule that upregulates a single microRNA (miR-124) in immune cells and reduces the production of various inflammatory cytokines and chemokines. Objective: We assessed the efficacy and safety of the standa

Externí odkaz: https://doaj.org/article/38018d98dfd24036bb65e23f3e7a3be0

Functional Exhaustion of Type I and II Interferons Production in Severe COVID-19 Patients

Autor: Caroline Ruetsch, Vesna Brglez, Marion Crémoni, Kévin Zorzi, Céline Fernandez, Sonia Boyer-Suavet, Sylvia Benzaken, Elisa Demonchy, Karine Risso, Johan Courjon, Eric Cua, Carole Ichai, Jean Dellamonica, Thierry Passeron, Barbara Seitz-Polski

Publikováno v: Frontiers in Medicine, Vol 7 (2021)

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged in Wuhan in December 2019 and has since spread across the world. Even though the majority of patients remain completely asymptomati

Externí odkaz: https://doaj.org/article/48c990ff4059493093e04572ac95e874

Raltegravir Inclusion Decreases CD4 T-Cells Intra-Cellular Viral Load and Increases CD4 and CD28 Positive T-Cells in Selected HIV Patients

Autor: Gaurav Kumar, Jacqueline Cottalorda-Dufayard, Rodolphe Garraffo, Francine De Salvador-Guillouët, Eric Cua, Pierre-Marie Roger

Publikováno v: Cells, Vol 11, Iss 2, p 208 (2022)

Raltegravir (RLT) prevents the integration of HIV DNA in the nucleus, but published studies remain controversial, suggesting that it does not decrease proviral DNA. However, there are only a few studies focused on virus-targeted cells. We aimed our s

Externí odkaz: https://doaj.org/article/912eb47b0b144f27b44fad18692fd397

Pleasure and PrEP: Pleasure-Seeking Plays a Role in Prevention Choices and Could Lead to PrEP Initiation

Autor: Xavier Mabire, Costanza Puppo, Stéphane Morel, Marion Mora, Daniela Rojas Castro, Julie Chas, Eric Cua, Claire Pintado, Marie Suzan-Monti, Bruno Spire, Jean-Michel Molina, Marie Préau

Publikováno v: American Journal of Men's Health, Vol 13 (2019)

Pleasure-seeking plays a role in prevention (means choices and use), and in the sexual quality of life of men who have sex with men (MSM). Since HIV is a major threat to MSM health, new means of prevention, like pre-exposure prophylaxis (PrEP), must

Externí odkaz: https://doaj.org/article/fc260bd98d9647fea1cc1a4a77483723

Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial

Autor: Onyema Ogbuagu, Peter J Ruane, Daniel Podzamczer, Laura C Salazar, Keith Henry, David M Asmuth, David Wohl, Richard Gilson, Yongwu Shao, Ramin Ebrahimi, Stephanie Cox, Alexander Kintu, Christoph Carter, Moupali Das, Jared M Baeten, Diana M Brainard, Gary Whitlock, Jason M Brunetta, Gitte Kronborg, Christoph D Spinner, Andrea Antinori, Vanessa Apea, David Asmuth, Ann Avery, Paul Benson, Colm Bergin, Mezgebe Berhe, Indira Brar, Cynthia Brinson, Jason Brunetta, Jeffrey Burack, Thomas Campbell, Michelle Cespedes, Amanda Clarke, Megan Coleman, Josep Coll, Manuel Crespo Casal, Catherine Creticos, Gordon Crofoot, Frederick Cruickshank, Eric Cua, Eric Daar, Joseph de Wet, Edwin DeJesus, Jorge Del Romero Guerrero, William Dinges, Susanne Doblecki-Lewis, Taylor Donovan, Olamide Dosekun, Jason Flamm, Joel Gallant, Jan Gerstoft, Jay Gladstein, Robert Grant, Robert Grossberg, Bernhard Haas, Jason Halperin, W. David Hardy, Charles Hare, Shawn Hassler, Richard Hengel, William Henry, Theo Hodge, Sybil Hosek, Christopher Hurt, Michelle Iandiorio, Heiko Jessen, Stephen Kegg, Gabriele Knecht, Ivanka Krznaric, Anthony LaMarca, Carsten Schade Larsen, Olav Ditlevsen Larsen, Adriano Lazzarin, Clifford Leen, Christopher Lucasti, Patrick Mallon, Sharon Mannheimer, Martin Markowitz, Claudia Martorell, Kenneth Mayer, Anthony Mills, Jean-Michel Molina, Sheldon Morris, Karam Mounzer, Nneka Nwokolo, Olayemi Osiyemi, Andrew Petroll, Patrick Philibert, John Phoenix, Gilles Pialoux, Frank Post, Maria Prins, Moti Ramgopal, Bruce Rashbaum, Iain Reeves, Gary Richmond, Armin Rieger, Peter Ruane, Laura Salazar, Anthony Scarsella, Gabriel Schembri, Mia Scott, Peter Shalit, Gary Sinclair, Magdalena Sobieszczyk, Christoph Spinner, Jeffrey Stephens, Jason Szabo, Stephen Taylor, Melanie Thompson, Cecile Tremblay, Benoit Trottier, Gene Voskuhl, Barbara Wade, Kimberly Workowski, Sigal Yawetz, Benjamin Young

Publikováno v: The Lancet HIV, 8(7), e397-e407. Elsevier Limited
DISCOVER study team 2021, ' Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis : week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial ', The Lancet HIV, vol. 8, no. 7, pp. e397-e407 . https://doi.org/10.1016/S2352-3018(21)00071-0

Summary Background In DISCOVER, a multinational, randomised controlled trial, emtricitabine and tenofovir alafenamide compared with emtricitabine and tenofovir disoproxil fumarate showed non-inferior efficacy for HIV prevention and improved bone mine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::303b5922ad83d78a448781b8c096428c
https://doi.org/10.1016/s2352-3018(21)00071-0